XML 50 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Revenues (Tables)

9 Months Ended

Sep. 30, 2014

Segment Reporting [Abstract]

Summary of net revenue

The Company’s net revenues consisted of the following for the three and nine months ended September 30, 2014 and 2013:

	Three months ended September 30,								Nine months ended September 30,
	2014				2013				2014				2013
Products:
Acetadote	$	3,242,014			$	3,770,302			$	9,026,919			$	15,169,270
Omeclamox-Pak	996,974				—				3,481,264
Kristalose	3,967,885				2,207,586				10,903,255				6,365,879
Vaprisol	653,070				—				2,022,835
Caldolor	821,024				484,651				1,950,106				1,510,622
Other	48,080				66,036				188,080				822,024
Total net revenues	$	9,729,047			$	6,528,575			$	27,572,459			$	23,867,795

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration